New NF-light™ Serum ELISA
The NF-light™ Serum ELISA has made it easy for every lab to research neurodegenerative diseases by measuring NF-light values in serum.
The first IVDR sIL-2R ELISA providing trustworthy results for aiding in the sarcoidosis diagnosis.
We’re excited to announce the availability of the sIL-2R ELISA kit (30201813), which is fully compliant with IVDR requirements, offering a reliable tool for sarcoidosis diagnostics. The kit has been CE marked under the European IVD Regulation 2017/746, ensuring you receive the most accurate and trustworthy results.
sIL-2R levels can be used as physiological marker for the indication of inflammation in the body, in-vivo immune system activation and response activity. As such the measurement of sIL-2R levels can be applied as an aid in the diagnosis or monitoring of therapy of autoimmune diseases (e.g. sarcoidosis).
Measuring levels of sIL-2R in adults are considered as a good parameter to determine on-going immune response, which can be used to monitor immune mediated diseases1.
This property is taken into account by several clinical guidelines. The German Society of Nephrology together with the German Clinical Chemistry and Laboratory Society recommend to measure sIL-2R together with other parameters in the diagnostic work-up of acute kidney failure to rule out a sarcoidosis origin2.
Furthermore, the German Ophthalmologic Society and the Professional Association of Ophthalmologists in Germany recommend in their clinical guidelines for optic neuritis also the measurement of sIL-2R to rule out a sarcoidotic background3. Another clinical guideline for the diagnostic of polyneuropathies from the German Society of Neurology also recommends to measure sIL-2R, if there is an indication of pulmonary involvement4.
• Trustworthy results: >95% specificity compared to established IVD solutions (N=216 from 7 different labs)
• Scalable solution: manual assay that can be easily automated (e.g. Thunderbolt®, DSX®, EVOlyzer®).
We gladly support you by keeping you updated on our latest products and the developments around our services.